Feed ENVB
EN

Enveric Biosciences, Inc.

ENVB · NASDAQ

$1.46 +0.69% (+$0.01)
1M -5.81%
Market Cap $871.6K
P/E Ratio -
Div. Yield -
ROE 168.05%

Bulios Fair Price

$2.02

38.4% upside

Trenutna cena

$1.46

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ENVB trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
100 /100
Cheap
P/B 0.11x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 34.21%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 107.99%
Asset turnover 0.00x
ROE 168.05%
Debt
69 /100
Low
Debt/Equity 0.00x
Int. coverage -10,329.20x
Current ratio 10.21x
Stability
27 /100
Unstable
Beta 1.11x
Profitable years 0
EPS volatility 115.68%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ENVB
Online

O podjetju

Enveric Biosciences Inc. (ENVB) is a biopharmaceutical company focused on developing innovative therapeutic products for the treatment of symptoms associated with cancer and other chronic diseases. The company specializes in the research and development of cannabinoid-based therapies and other natural compounds that offer patients hope for relief from pain, inflammation, and other challenges associated with illness.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Joseph Edward Tucker

Employees

6

Headquarters

Cambridge

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

62d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.